Overview

The optimal care of patients with breast cancer is rapidly changing as a result of advances in all aspects of patient care, including prevention, screening, and detection, as well as in the primary treatment modalities of surgery, radiation therapy, endocrine therapy, cytotoxic chemotherapy, and novel biologic therapies. There is an increasing focus on providing multidisciplinary care for patients with complex diseases such as breast cancer through the use of integrated teams of professionals representing the relevant treatment modalities, including surgery, radiation therapy, and systemic medi­cal interventions. The multidisciplinary Miami Breast Cancer Conference^® has been bringing together surgical, medical, and radiation oncologists for 30 years, with the aim of fostering awareness of the state-of-the-art treatments in each therapeutic area and encouraging cross-team cooperation in the clinic. At the 30th Annual Miami Breast Cancer Conference^®, pioneers of innovative approaches in each of these subspecial­ties will provide insight into the optimal multidisciplinary management of patients with breast cancer and its application to practice.

Target Audience

This educational program is directed toward medical, surgical, and radiation oncologists interested in the treatment of patients with breast cancer. Fellows, nurse practitioners, nurses, physician assistants, researchers, and other health care professionals interested in the treatment of breast cancer are also invited to attend.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

• Discuss breast carcinogenesis, the impact of germline mutations and breast cancer biology on patient management, and strategies for breast cancer risk reduction
• Incorporate current guidelines and recent data on local therapy, including new strategies for surgical and radiation therapy, into the treatment of patients with breast cancer
• Integrate biomarkers, molecular assays, and other risk assessment tools in treatment decision making for breast cancer when appropriate
• Incorporate systemic therapies for breast cancer (including endocrine, cytotoxic, targeted, and bone-modifying agents) into individualized treatment plans for patients based upon an evaluation of efficacy and safety, as well as patient characteristics and tumor subtype
• Evaluate emerging clinical data regarding new agents and evolving strategies for the treatment of breast cancer, and apply clinical trial data appropriately in order to optimize the outcome of individual patients
• Utilize optimal strategies for preventing and treating breast cancer therapy-related side effects
• Select eligible patients with breast cancer for promising clinical trials

Poster Discussion

March 7, 2013
Fontaine Room
7:00 pm
 
Join us for the PER SABCS poster session. Our posters will provide you with:

• Top Data from SABCS
• Key take home points
• Implications for your practice

The PER SABCS poster sessions offers attendees of the Miami Beast Cancer Conference a unique opportunity, top thought leaders in breast cancer, Hope Rugo and Patrick Borgen will review the top presentations from the recent San Antonio Breast Cancer Symposium.  The posters will be created from presentations that have the greatest potential to change practice.  Each poster will be reviewed and the take home points and implications for practice discussed.  Posters can be found in the poster gallery located in the exhibit hall (sparkle west).  The poster discussion will be available to all attendees Thursday evening after the welcome reception in Fontaine.

Mini-Symposium

The 2013 Miami Breast Cancer Conference^® Mini-Symposium offers an additional educational opportunity for attendees who plan to arrive in Miami the day before the official conference begins. This year’s Mini-Symposium features topics of practical importance for physicians and their patients, including:

• Managing side effects of surgical and medical treatments
• Host factors that increase breast cancer risk
• Utilizing blood tests for early detection and treatment
• Biopsies for recurrent disease
• Practice-changing updates from San Antonio and ASCO
• Dealing with physician burn-out

This special session was developed to be of interest to health care practitioners from all specialties, and will provide practical information to enhance patient care in the clinic, delivered by top experts in the field of breast cancer. If your schedule allows, plan to attend and take advantage of this extra session!

Chair

Daniel A. Osman, MD
Breast Cancer Surgeon
Miami, FL

Program Directors

Patrick Borgen, MD
Chairman, Department of Surgery, Maimonides Hospital
Director, Brooklyn Breast Cancer Program
Brooklyn, NY

Robert DerHagopian, MD
Medical Director
Baptist Health Breast Center
Miami, FL
 
J. Michael Dixon, MD
Professor of Surgery & Consultant Surgeon
Clinical Director, Breakthrough Research Unit
 Edinburgh Breast Unit, Edinburgh, UK
 
Debu Tripathy, MD
Professor of Medicine
University of Southern California
Norris Comprehensive Care Center
Los Angeles, CA

Faculty

Fabrice Andre, MD
Breast Cancer Unit, Department of Medical Oncology
Institut Gustave Roussy
France
 
Samuel Aparicio, MD
Professor of Pathology & Medicine
University of British Columbia
Vancouver, Ca
 
Jose Baselga, MD
Associate Director
Chief of Hematology/Oncology
Massachusetts General Cancer Center
Boston, MA
 
Lisa Carey, MD
Professor of Medicine
University of North Carolina at Chapel Hill
Chapel Hill, NC

Abigail S. Caudle, MD
Assistant Professor
Department of Surgical Oncology
Division of Surgery
The University of Texas
MD Anderson Cancer Center
Houston, TX
 
Anees Chagpar, MD
Associate Professor of Surgery
Yale University
Hartford, CT
 
Laura Esserman, MD, MBA
Professor, Department of Surgery & Radiology
UCSF
San Francisco, CA
 
Lloyd Gayle, MD
Clinical Associate Professor of Surgery
Weill Cornell Medical College
New York, NY
 
William J. Gradishar, MD
Professor of Medicine & Director, Breast Medical Oncology
Northwestern University
Feinberg School of Medicine
Chicago, IL
 
Mattia Intra, MD
Department of Breast Surgery
European Institute of Oncology
Milan, Italy
 
Elizabeth Morris, MD
Director, Breast MRI, Department of Radiology
Memorial Sloan-Kettering Cancer Center
New York, NY
 
Hyman Muss, MD
Professor of Oncology
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
 
Mark Pegram, MD
Director of Breast Oncology
Stanford School of Medicine
Stanford, CA
 
Charles M. Perou, PhD
Professor
University of North Carolina at Chapel Hill
Chapel Hill, NC
 
Emanuel F. Petricoin III, PhD
Co-Director, Center for Applied Proteomics & Molecular Medicine
Professor of Life Sciences
George Mason University
Manassas, VA
 
Martine Piccart, MD, PhD
Head, Department of Medicine
Jules Bordet Institute;
Chairwoman of the Breast International Group;
President of EORTC
Brussels, Belgium
 
Hope S. Rugo, MD
Clinical Professor of Medicine
University of California at San Francisco
San Francisco, CA
 
Virgilio Sacchini, MD
Attending, Breast Service
Memorial Sloan Kettering Cancer Center
New York, NY

Donna Shalala
President, University of Miami
Professor, Political Science
Miami, FL
 
George Sledge Jr., MD
Professor of Medicine, Hematology-Oncology
Indiana University School of Medicine
Indianapolis, IN
 
Lawrence J. Solin, MD, FACR, FASTRO
Chair, Radiation Oncology
Albert Einstein Healthcare Network
University of Pennsylvania
Philadelphia, PA
 
Fraser Symmans, MD
Pathology Dept
MD Anderson Cancer Center
Houston, TX
 
Gunter von Minckwitz, MD
Chairman, German Breast Group & Professor of Gynecology
University of Frankfurt
Frankfurt, Germany
 
Tim Whelan, BM, BCh (Oxford), MSc (McMaster), LMCC, DABIM, FRCP(C)
Professor of Medicine, Division of Radiation Oncology
McMaster University & Juravinski Cancer Center
Hamilton, Ontario
 
Norman Wolmark, MD
Chairman, National Surgical Adjuvant Breast & Bowel Project (N.S.A.B.P.)
Pittsburgh, PA

• Thursday, March 7, 2013 (Mini-Symposium)
• Friday, March 8, 2013
• Saturday, March 9, 2013
• Sunday, March 10, 2013

Thursday, March 7, 2013 (Mini-Symposium)
12:50 PM	Welcome	Daniel A. Osman, MD
	Practical Issues for Patients and Physicians
1:00 PM	When Do You Need a PET/CT or MRI in Early Breast Cancer?	Elizabeth Morris, MD
1:15 PM	The Use of Blood Tests in Breast Cancer for Early Detection and Treatment	Emanuel F. Petricoin III, PhD
1:30 PM	What Are the Long-Term Side Effects of Chemotherapy and Endocrine Treatment and How to Combat Them	Hyman Muss, MD
1:50 PM	Management of Early Menopausal Associated Symptoms in Patients with Breast Cancer	J. Michael Dixon, MD
2:05 PM	Host Factors That Increase Breast Cancer Risk	Debu Tripathy, MD
2:20 PM	What Patients Can/Cannot Do After Axillary Surgery	Anees Chagpar, MD, MSc, MA, MPH
2:35 PM	BREAK
3:20 PM	BRCA Gene at Age 20: What Have We Learned?	Patrick I. Borgen, MD
3:35 PM	The Need for Repeat Biopsy After Recurrence	Anees Chagpar, MD, MSc, MA, MPH
3:50 PM	How Do You Treat Chemotherapy-Induced Nausea and Vomiting?	Hope S. Rugo, MD
4:05 PM	ASCO and San Antonio Updates	Debu Tripathy, MD
4:20 PM	Panel Discussion
5:20 PM	Adjourn
6:00 PM	Welcome Reception (Exhibit Hall)
7:00 PM	Poster Discussion (General Session Room)
Friday, March 8, 2013 (Morning Session)
7:50 AM	Welcome	Daniel A. Osman, MD
8:00 AM	Putting Genomics Into Clinical Practice	Charles M. Perou, PhD
8:15 AM	Use of Genomic Approaches to Select Patients for Targeted Therapy	Fabrice André, MD, PhD
8:30 AM	Which Translational Research Is Ready for Prime Time?	Martine Piccart, MD, PhD
8:45 AM	Kinome Profiling: The Potential in ER-Negative Patients	Charles M. Perou, PhD
9:00 AM	Intratumoral Heterogeneity in the Primary Tumor and Mutational Evolution on Progression	Samuel Aparicio, PhD
9:15 AM	The Role of Stem Cells in Tumorgenesis- Can We Identify and Inhibit Them?	W. Fraser Symmans, MD
	DCIS and Early Breast Cancer
9:30 AM	Are We Overdiagnosing and Overtreating DCIS?	Laura Esserman, MD, MBA
9:45 AM	Is Gene Expression Profiling the Best Method for Selecting Systemic Therapy?	Norman Wolmark, MD
10:00 AM	BREAK
10:45 AM	Selecting Individualized Treatment for Patients with DCIS	Lawrence J. Solin, MD, FACR, FASTRO
11:00 AM	Re-evaluating Axillary Dissection	Virgilio Sacchini, MD
11:15 AM	Targeting Surgery for Known Axillary Disease	Abigail S. Caudle, MD
11:30 AM	Should Hypofractionation Be the New Standard After Breast Conserving Surgery?	Timothy Whelan, BM, BCh (Oxford), MSc (McMaster), LMCC, DABIM, FRCP(C)
11:45 AM	Panel Discussion
12:45 PM	LUNCH
Friday, March 8, 2013 (Session A)		Moderator: J. Michael Dixon, MD
2:00 PM	DEBATE: Does Regional Radiation Improve Outcome?	Moderator: Patrick I. Borgen, MD
	For	Timothy Whelan, BM, BCh (Oxford), MSc (McMaster), LMCC, DABIM, FRCP(C)
	Against	J. Michael Dixon, MD
	"How I Do It"
2:30 PM	Skin- and Nipple-Sparing Mastectomy	Virgilio Sacchini, MD
2:45 PM	Main Factors That Influence Incomplete Excision After Breast-Conserving Surgery	J. Michael Dixon, MD
3:00 PM	Intraoperative Radiotherapy	Mattia Intra, MD
3:15 PM	Current Update on the Standard of Care for Accelerated Partial-Breast Radiotherapy-Technique, Efficacy, Toxicities	Lawrence J. Solin, MD, FACR, FASTRO
3:30 PM	Therapeutic Mammoplasty: Who, How, How Often?	Lloyd Gayle, MD
3:45 PM	Options in the Management of Central Breast Tumors	Mattia Intra, MD
4:00 PM	BREAK
4:45 PM	Lipofilling: A New Technique for All	Lloyd Gayle, MD
5:00 PM	Imaging After Oncoplastic Surgery	Elizabeth Morris, MD
5:15 PM	Panel Discussion
5:45 PM	Adjourn
Friday, March 8, 2013 (Session B)		Moderator: Debu Tripathy, MD
2:00 PM	Is Sentinel Node Biopsy Increasingly Irrevelant in Lieu of Gene Profiling for Prognosis and Prediction?	Hyman Muss, MD
2:15 PM	Alternate Gene Signatures	Charles M. Perou, PhD
2:30 PM	Tailoring Adjuvant Hormonal Therapy	Lisa Carey, MD
2:45 PM	Non-Anthracycline Adjuvant Therapy: When to Use?	William J. Gradishar, MD
3:00 PM	Adjuvant Therapy for HER2+ Breast Cancer: 1 vs 2 Years	Martine Piccart, MD, PhD
3:15 PM	Adjuvant Therapy for Older Individuals	Hyman Muss, MD
3:30 PM	Predicting Survival From Adjuvant Therapy	W. Fraser Symmans, MD
3:45 PM	Targeting Tumor Vasculature- How to Move Forward?	Hope S. Rugo, MD
4:00 PM	BREAK
4:45 PM	Circulating Tumor Cells: What Do They Tell Us?	Emanuel F. Petricoin III, PhD
5:00 PM	Panel Discussion (Difficult Adjuvant Cases)	Moderator: Debu Tripathy, MD
5:45 PM	Adjourn
6:15 PM	Get Acquainted Reception (Exhibit Hall)
Saturday, March 9, 2013 (Morning Session)		Moderator: Debu Tripathy, MD
8:00 AM	Affordable Health Care Act: What It Means for the Physician and the Patient	Donna Shalala
8:30 AM	The Challenges and the Promises of the Genomic Era	George Sledge Jr, MD
8:45 AM	Breast Cancer Subgroups and Their Molecular Drivers	Samuel Aparicio, PhD
9:00 AM	Managing Triple-Negative Tumors in Everyday Practice	Lisa Carey, MD
9:15 AM	Immunoconjugates in Both the Adjuvant and Metastatic Setting	Mark Pegram, MD
9:30 AM	mTOR Inhibitors: Reversing Resistance to Endocrine Blockade Therapy	José Baselga, MD, PhD
	Pre-Operative Therapy
9:45 AM	Lessons Learned From Pre-operative Therapy	Gunter von Minckwitz, MD, PhD
10:00 AM	BREAK
10:45 AM	Predictive Immunohistochemical Biomarkers in the Context of Neoadjuvant Therapy	W. Fraser Symmans, MD
11:00 AM	Biomarker Implementation: Which Model?	Fabrice André, MD, PhD
11:15 AM	Neoadjuvant Therapy to Select the Most Effective Drug Combination (I-SPY Trial)	Laura Esserman, MD, MBA
11:30 AM	Protein Pathway Mapping: Realizing the Promise of Individualized Therapy at the Bedside	Emanuel F. Petricoin III, PhD
11:45 AM	Assessing Response to Neoadjuvant Therapy	Elizabeth Morris, MD
12:00 PM	Should Response to Pre-operative Therapy Tailor Radiation, Chemotherapy, Surgical Care?	Gunter von Minckwitz, MD, PhD
12:15 PM	Panel Discussion
1:00 PM	LUNCH
Saturday, March 9, 2013 (Session A)		Moderator: Patrick I. Borgen, MD
2:15 PM	Sentinel Node Biopsy After Pre-operative Therapy	Anees Chagpar, MD, MSc, MA, MPH
2:30 PM	Management of Uncommon Cancers of the Breast	Virgilio Sacchini, MD
2:45 PM	Invasive Lobular Carcinoma: Subtypes and Outcomes	Mattia Intra, MD
3:00 PM	Contralateral Prophylactic Mastectomies: Risks and Benefits	Patrick I. Borgen, MD
3:15 PM	DEBATE: Are We Doing Too Many Mastectomies?
	Yes	J. Michael Dixon, MD
	No	Patrick I. Borgen, MD
3:45 PM	Does Everyone With 1-3+ Nodes Need Post-Mastectomy Radiotherapy?	Lawrence J. Solin, MD, FACR, FASTRO
4:00 PM	What Is New in Breast Reconstruction?	Lloyd Gayle, MD
4:15 PM	BREAK
4:45 PM	Is There Value to Local Control in Selected Patients with Stage IV Disease?	Anees Chagpar, MD, MSc, MA, MPH
5:00 PM	Panel Discussion
6:00 PM	Adjourn
Saturday, March 9, 2013 (Session B)		Moderator: Debu Tripathy, MD
2:15 PM	My Viewpoint: Can Pathologic Response to Neoadjuvant Therapy Be an FDA- Approvable Endpoint?	Laura Esserman, MD, MBA
2:25 PM	My Viewpoint: Can Pathologic Response to Neoadjuvant Therapy Be an FDA- Approvable Endpoint?	Norman Wolmark, MD
2:35 PM	My Viewpoint: Can Pathologic Response to Neoadjuvant Therapy Be an FDA- Approvable Endpoint?	Gunter von Minckwitz, MD, PhD
2:45 PM	Panel Case  Discussion on Neoadjuvant Therapy
3:15 PM	Front-line Chemotherapy for Advanced Breast Cancer: Is There a Standard?	Hope S. Rugo, MD
3:30 PM	Chemotherapeutic Choices in Later Lines of Therapy	William J. Gradishar, MD
3:45 PM	Mutational Evolution in Triple-Negative Breast Cancer	Samuel Aparicio, PhD
4:00 PM	Progress in Treating Advanced Triple-Negative Breast Cancer	Lisa Carey, MD
4:15 PM	BREAK
4:45 PM	Advanced HER2+ Breast Cancer: New Options and How to Deploy Them	José Baselga, MD, PhD
5:00 PM	Combination of Two Anti HER2 Therapies	Mark Pegram, MD
5:15 PM	Panel Discussion
6:00 PM	Adjourn
7:00 PM	Closing Reception
Sunday, March 10, 2013		Moderators: J. Michael Dixon, MD Patrick I. Borgen, MD
8:15 AM	Future Direction for NSABP: Clinical Trial Design in an Impatient World	Norman Wolmark, MD
8:30 AM	Future Prediction for Adjuvant Therapy	George Sledge Jr, MD
8:45 AM	Predicting Bone Metastasis with Micro RNAs	Fabrice André, MD, PhD
9:00 AM	Adjuvant Bisphosphonates: Has the Time Come?	William J. Gradishar, MD
9:15 AM	Update on the New P13K Inhibitors	José Baselga, MD, PhD
9:30 AM	Strategies to Overcome Resistance to Trastuzumab	Mark Pegram, MD
9:45 AM	The Role of Epigenetics in Breast Cancer	W. Fraser Symmans, MD
10:00 AM	Rethinking the Metastatic Cascade as a Therapeutic Target	George Sledge Jr, MD
10:15 AM	BREAK
10:45 AM	Panel Discussion
12:00 PM	Adjourn

The 30^th Annual Miami Breast Cancer Conference® was a multidisciplinary success.
 
For those who were unable to attend our 30^th Annual Miami Breast Cancer Conference®, you may now take advantage of a sneak peek at the successful meeting. Over 1,100 surgeons and medical oncologists joined us and engaged with national and international leaders in breast cancer.

This year’s meeting was a milestone where we celebrated and honored Dr and Mrs Daniel A. Osman who have chaired the meeting for thirty years.

Click below for a video sampling of the conference:


 
To register for the 31^st Annual Miami Breast Cancer Conference® click here.

Need a refresh on what you learned at 30th Annual Miami Breast Cancer Conference® or unable to attend 30th Annual Miami Breast Cancer Conference®? Don't worry.  Miami Breast Cancer Conference® 2013 online CME will be available in May.

---